RA’ANANA, Israel, Jan. 10, 2025 /PRNewswire/ — Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (“Inspira” or the “Company”), a leader in life support technology innovation, announced today that it is preparing for a potential ramp-up of production of the INSPIRA™ ART100 device. This strategic readiness stems from the recent outbreak of human metapneumovirus (hMPV) in Chinawhich highlights the growing need for advanced respiratory care technologies worldwide.

Inspira is already in discussions with leading providers in the affected regions to assess the need for advance respiratory solutions and deploy the INSPIRA™ ART100 device, ensuring rapid response capabilities in case of further that need.

As global health authorities monitor the outbreak of hMPV, Inspira™ believes it is well positioned to meet the potential increase in demand for advanced respiratory support systems. Inspira works closely with suppliers to ensure the necessary raw materials and components to meet potential increases in demand. The Company is following the hMPV situation worldwide and is working to revise production plans as necessary.

“While hMPV is not a new virus, and experts indicate that the current outbreak is part of normal weather patterns, Inspira believes in being prepared,” said Dagi Ben-Noon, CEO of Inspira. “Our increased production capacity will help ensure that healthcare providers have access to critical respiratory care equipment when the need arises.”

Inspira emphasized that its preparedness measures are precautionary and consistent with the Company’s commitment to global health preparedness. The Company will closely cooperate with health authorities in the affected regions and adjust its plans based on the evolving situation.

Inspira™ Technologies OXY BHN Ltd.

Inspira Technologies is an innovative medical technology company in the life support and respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA ™ ART), a groundbreaking device poised to revolutionize the $19 billion mechanical ventilation market. With 20 million intensive care unit patients with acute respiratory failure every year, most of them dependent on mechanical ventilators, INSPIRA ART offers a potential alternative by increasing and stabilizing the reduced saturation level of oxygen in minutes without a ventilator, with patients awake during treatment. INSPIRA ART is equipped with a clip-on HYLA™ blood sensor, a real-time continuous blood monitoring technology, which aims to alert doctors to changes in one’s condition patients without the need for intermittent actual blood samples, which aims to support doctors in making. informed decisions.

In June and July 2024respectively, the Company’s INSPIRA^™ The ART100 system has obtained FDA 510 (k) clearance for use in CBP procedures, along with Israel’s AMAR certification for Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures.

The Company’s other products and technologies, including INSPIRA ART also known as INSPIRA™ ART500 or Gen 2, the INSPIRA™ Cardi-ART portable modular device, VORTX™ Oxygen Delivery System, and HYLA™ blood sensor, are currently being designed and developed. , and has not been tested or used by humans or approved by any regulatory entity.

For more information, please visit our corporate website at https://inspira-technologies.com

Forward-Looking Statement Disclaimer This press release contains expressed or implied forward-looking statements in accordance with US Federal securities laws. These forward-looking statements are based on the current expectations of the Company’s management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company uses forward-looking statements when it discusses the growing demand for advanced respiratory care technologies and its ability to adjust its plans to respond rapidly if there is an increase in demand. . These forward-looking statements and their implications are based only on the current expectations of the Company’s management and are subject to numerous factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by law, the Company has no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unforeseen events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s annual report on Form 20-F for the fiscal year ended. December 31, 2023filed in US Securities and Exchange Commission (the “DECLARED by SEC“), which is in SECs website of www.sec.gov.

Contact: Inspira Technologies ” Media Relations
Email: [email protected]
Phone: +972-9-9664485

MRK-ARS-113

Copyright © 2018-2025 Inspira Technologies OXY BHN LTD., All rights reserved.

Logo: https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg